WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in systemic reactogenicity eventse compared with placebo (high certainty).
WIBP‐CorV – Sinopharm‐Wuhan leads to lower any adverse eventh compared with placebo (high certainty).
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
WIBP‐CorV – Sinopharm‐Wuhan leads to lower local reactogenicity eventsk compared with placebo (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in systemic reactogenicity eventse compared with placebo (moderate certainty).
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
The review found no eligible studies for this question.
BBV152 – Bharat Biotech showed no clear difference in all‐cause mortalitye compared with placebo (low certainty).
BBV152 – Bharat Biotech leads to higher systemic reactogenicity eventsg compared with placebo (high certainty).
BBV152 – Bharat Biotech showed no clear difference in any adverse eventi compared with placebo (high certainty).